News
Corporate News
- 2022
- 11/21 Published 5th financial report
- 10/03 Chordia Therapeutics Director and Statutory Auditor Appointments
- 09/08 Chordia named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022
- 08/29 Chordia’s licensee Ono Pharmaceutical Co., Ltd. initiated Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
- 06/07 Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
- 06/07 Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd
- 05/19 Concludes Basic Agreement on Business Tie up with MEDIPAL HOLDINGS CORPORATION
- 05/19 Raises Approximately 4 billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 billion JPY
- 05/16 Featured as a cover story in Startup City Magazine’s “Top 10 Japanese Startups 2022”
- 04/07 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022
- 2021
- 12/03 Published 4th financial report
- 09/24 Assignment of Statutory Auditor
- 03/03 Published in Scrip
- 02/04 Published in Answernews
- 2019
- 10/25 Chordia Therapeutics announced the appointment of CMO & CSO
- 03/29 Chordia Therapeutics Raises $~27 million in Series B Financing
- 01/10 Published our article in Forbes JAPAN
- 2017
- 11/30 Chordia Therapeutics Raises $~11 million in Series A Financing
- 11/22 Launch of Chordia Therapeutics